ISRIB is licensed by Calico which recently initiated phase I trials for its use in ALS (https://www.massgeneral.org/news/press-release/investigational-drug-init

ISRIB is licensed by Calico which recently initiated phase I trials for its use in ALS (https://www.massgeneral.org/news/press-release/investigational-drug-initiates-design-phase-for-healey-als-trial https://www.massgeneral.org/news/press-release/investigation...)